Effect of melphalan 140 mg/m2vs 200 mg/m2on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantation-a single center experience-Reference-Cited by-同舟云学术

Effect of melphalan 140 mg/m2vs 200 mg/m2on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantation-a single center experience

Published:2016-06-29 Issue:8 Volume:30 Page:894-900
ISSN:0902-0063
Container-title:Clinical Transplantation
language:en
Short-container-title:Clin Transplant

Author:

Katragadda Lakshmikanth¹,McCullough Lindsay M.¹,Dai Yunfeng²,Hsu Jack¹,Byrne Michael³,Hiemenz John¹,May Stratford¹,Cogle Christopher R.¹,Norkin Maxim¹,Brown Randy A.¹,Wingard John R.¹,Chang Myron²,Moreb Jan S.¹

Affiliation:

1. Department of Medicine; University of Florida; Gainesville FL USA

2. Department of Biostatistics; University of Florida; Gainesville FL USA

3. Department of Medicine; University of Vanderbilt; Nashville TN USA

Publisher

Wiley

Subject

Transplantation

Reference47 articles.

1. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome;Attal;N Engl J Med,1996

2. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial;Palumbo;Blood,2004

3. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe;Fermand;J Clin Oncol,2005